Evidence map›Paper›PMID 39020454›Full record

ArticleJournal of the International AIDS Society2024

Client experiences with "Dynamic Choice Prevention," a model for flexible patient-centred HIV prevention delivery in rural Eastern Africa.

Carol S Camlin, Titus Arunga, Jason Johnson-Peretz, Cecilia Akatukwasa, Fredrick Atwine, Angeline Onyango, Lawrence Owino, Moses R Kamya, Maya L Petersen, Gabriel Chamie and 5 more

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Assessing pharmacy workflow to enhance the integration of HIV prevention services.Journal of the American Pharmacists Association : JAPhA
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Carol S CamlinUniversity of California, San Francisco (UCSF), Obstetrics, Gynecology & Reproductive Sciences, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-5615-1164
Titus ArungaKenya Medical Research Institute (KEMRI), Kisumu, Kenya.
Jason Johnson-PeretzUniversity of California, San Francisco (UCSF), Obstetrics, Gynecology & Reproductive Sciences, San Francisco, California, USA.
Cecilia AkatukwasaInfectious Diseases Research Collaboration, Kampala, Uganda.
Fredrick AtwineInfectious Diseases Research Collaboration, Kampala, Uganda.
Angeline OnyangoKenya Medical Research Institute (KEMRI), Kisumu, Kenya.
Lawrence OwinoKenya Medical Research Institute (KEMRI), Kisumu, Kenya.
Moses R KamyaInfectious Diseases Research Collaboration, Kampala, Uganda.
Maya L PetersenUniversity of California, Berkeley, Biostatistics, Epidemiology, and Computational Precision Health, Berkeley, California, USA.
Gabriel ChamieUniversity of California, San Francisco (UCSF), Medicine, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-5860-8081
Elijah KakandeInfectious Diseases Research Collaboration, Kampala, Uganda.ORCID https://orcid.org/0000-0001-9532-5710
Jane KabamiInfectious Diseases Research Collaboration, Kampala, Uganda.
Laura B BalzerUniversity of California, Berkeley, Biostatistics, Epidemiology, and Computational Precision Health, Berkeley, California, USA.
Diane V HavlirUniversity of California, San Francisco (UCSF), Medicine, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-0761-3136
James AyiekoKenya Medical Research Institute (KEMRI), Kisumu, Kenya.ORCID https://orcid.org/0000-0002-0324-4006

Funding

A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East AfricaU01AI150510 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V, KAMYA, MOSES ROBERT · 2020 to 2025
$23.4M
National Heart, Lung, and Blood Institute (NHLBI)National Institute of Mental Health (NIMH) U01AI150510NIAID NIH HHS U01 AI150510U.S. National Institute of Allergy and Infectious Diseases (NIAID)
6 · The paper itself

Abstract

introductionIdentifying the optimal approaches to offering HIV prevention to meet the needs of those at risk is a high priority, particularly given the expanding toolkit of biomedical HIV prevention options. An ongoing study in rural East African communities evaluated the uptake of choices in product, testing mode and location of care delivery through a structured patient-centred HIV prevention delivery model. In this qualitative study, we sought to understand clients' experiences of this "dynamic choice prevention model" (DCP) and highlight pathways of action to inform HIV prevention delivery models.

methodsIn-depth semi-structured interviews were conducted from November 2021 through March 2022 with a purposively selected sample of n = 56 participants in DCP trials (across outpatient departments, antenatal clinics and community settings), and n = 21 healthcare providers (total n = 77). A seven-person multi-regional team translated and inductively coded transcript data. We used a framework analysis approach to identify emergent themes.

resultsIndividuals taking up HIV pre-exposure prophylaxis (PrEP) reported feelings of relief, liberation from fears of acquiring HIV and satisfaction with being able to take action despite partners' behaviours. Couples used a range of approaches afforded by the study to persuade partners to get tested and opt for PrEP. Post-exposure prophylaxis (PEP) use was less common, although women welcomed it in the event of sexual coercion or assault. Participants discussed switching from PEP to PrEP after familiarizing themselves with usage and ascertaining ongoing risk. Participants felt respected by providers, trusted them and appreciated being able to contact them directly for telephone support. Prevention uptake was hindered by stigma, limited experience with and knowledge of prevention methods, gendered and generational power dynamics within intimate partnerships and families, and negative perceptions of methods due to the products themselves. Participants anticipated long-acting injectable PrEP could solve their challenges regarding pill size, daily pill burden and the likelihood of unwanted disclosure.

conclusionsDiverse preferences and barriers to uptake of prevention require a choice of HIV prevention options, locations and delivery modalities-but in addition, flexible, competent and friendly care provision is crucial to promote uptake. Helping clients feel valued, and addressing their unique needs and challenges, enables their agency to prioritize their health.

Indexed as

HIV InfectionsPre-Exposure ProphylaxisRural PopulationAdultAfrica, EasternAnti-HIV AgentsFemaleHumansInterviews as TopicMaleMiddle AgedPatient-Centered CareQualitative ResearchYoung AdultAnti-HIV Agentsdifferentiated careHIV self‐testingHIV stigmapost‐exposure prophylaxispre‐exposure prophylaxissub‐Saharan Africa

Identifiers

PMID39020454
PMCPMC11254577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.